Table 1.

Summary of overall survival (full analysis set)

Parameters	Everolimus plus octreotide LAR	Placebo plus octreotide LAR
	(n = 216)	(n = 213)
No. of events, n (%)	143 (66.2)	128 (60.1)
No. censored, n (%)	73 (33.8)	85 (39.9)
Survival rate at
Year 1, % (95% CI)	80.5 (74.5–85.3)	81.8 (75.8–86.4)
Year 2, % (95% CI)	57.0 (49.9–63.4)	63.6 (56.6–69.8)
Year 3, % (95% CI)	42.9 (36.0–49.6)	48.5 (41.4–55.3)
Year 4, % (95% CI)	37.4 (30.7–44.1)	41.7 (34.7–48.6)
Median OS (95% CI), months	29.2 (23.8–35.9)	35.2 (30.0–44.7)
	HR (95% CI), 1.17 (0.92–1.49)

CI, confidence interval; HR, hazard ratio; LAR, long-acting repeatable; OS, overall survival.